Université Pierre Et Marie Curie (Paris Vi)

Other

Université Pierre Et Marie Curie

L'universite Pierre Et Marie Curie

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Assistance Publique-hopitaux De Paris

Université Pierre Et Marie Curie (Paris 6)

Aventis Pharma S.a.

L'université Pierre Et Marie Curie - (paris 6)

Genopoietic

Jean-Loup Salzmann

David Klatzmann

Bertrand Bellier

Michel Perricaudet

Patrice Yeh

Francois-Loic Cosset

Philippe Kourilsky

Claude Roth

Lluis M Mir

Christophe Torrent

François-Loïc Cosset

Charlotte Fribert

Georg Holzer

Arnaud Morel

Andr&egrave;s Crespo

Charlotte Frisen

Norbert Passuti

François-Loic Cosset

Theodora Hatziiannou

The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.

Synthetic viruses and uses thereof

The invention concerns a packaging eukaryotic cell for the production of defective infections viruses carrying a transgene, characterized in that it is deficient in one cell function essential to its growth, in particular in the presence of a selection culture medium, the function being capable of being restored by the expression of an exogenous sequence introduced in the cell: either with a vector carrying transcomplementing functions of packaging cells; or with a vector carrying a transgene, and enabling the selection in a selective medium of cells carrying the said exogenous sequence.

Highly productive packaging lines

The invention concerns methods and constructs for producing retroviral particles, in vitro, ex vivo or in vivo. It also concerns the use of said methods and constructs for transferring nucleic acids into cells. More particularly, the invention concerns a composition comprising the whole set of genetic elements required for constituting a retroviral particle, incorporated in one or several recombinant adenoviruses defective for all or part of the regions E1 and E4 at least (adenoviral/retroviral chimeric vectors).

Methods and compositions for producing viral particles

The invention relates to the use of replicating or semi-replicating viral construct(s) for the preparation of a composition for gene delivery into cells in vivo, ex vivo or in vitro. The invention also relates to novel retroviral constructs, packaging cells and nucleic acids which can be used in methods of delivering polynucleotides to cells.

Replicating or semi-replicating viral constructs, preparation and uses for gene delivery

This invention concerns compositions of chondrocytic cells, notably human ones, and the methods for preparing and using them. More specifically, the invention describes the production of autologous human chondrocyte suspensions, employing recombinant enzymes and/or media that are compatible with pharmaceutical use. The invention also describes methods and compositions for freezing chondrocytes, notably in the absence of DMSO. The chondrocytes which are produced can be used in vivo to restore affected cartilaginous structures, such as in post-traumatic cartilaginous defects or dissecting osteochondrite of the knee or, more generally, for treating and repairing clinically significant defects in cartilage, notably in joint cartilage.

Compositions of chondrocytes, preparation and utilization

The present invention relates to a vaccine consisting of defective viral particles as are obtained in vivo or ex vivo, in individuals infected or capable of being infected with a virus, after expression of the genes carried by a vector or a combination of vectors and comprising at least the structural genes necessary for the constitution of the viral particle.

Defective viral vaccine particles obtained in vivo or ex vivo

Composition for use in the treatment of tumors and the immunization of humans or animals comprising a synergistic association of cells, viruses, or bacteria expressing, transitorily, in organisms at least one gene for producing in vivo one or more immunomodulators, and viruses, or cells producing viruses, said viruses preferably infecting dividing cells of the treated organisms and carrying within their genome at least one gene whose expression in the dividing cells will cause their destruction.

Composition comprising interleukin-2 and thymidine kinase for the

Host-vector system which can be used in gene therapy

Cultured fibroblast or epithelial cell dissociation method using

Growing community of inventors

Paris, France

Jean-Loup Salzmann